NCT03976869 - A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 24, 2019

Primary Completion Date

July 9, 2020

Study Completion Date

July 9, 2020

Conditions

Asthma

Interventions

DRUG

AZD7594

During treatment period, AZD7594 (360 µg per day) will be administered as oral inhalation via dry powder inhaler or DPI (SD3FL inhaler).

Trial Locations (10)

Research Site, Bethesda

Research Site, Miami Lakes

Research Site, Miami

Research Site, Columbus

Research Site, Kansas City

Research Site, Oklahoma City

Research Site, Dallas

Research Site, Boerne

Research Site, Murray

Research Site, Rolling Hills Estates